TIDMFUM
RNS Number : 4981Q
Futura Medical PLC
28 October 2021
28 October 2021
Futura Medical plc
("Futura" or the "Company")
Board Appointment
Futura Medical plc (AIM: FUM), a pharmaceutical company
developing a portfolio of innovative products based on its
proprietary, transdermal DermaSys(R) drug delivery technology and
currently focused on sexual health and pain, is pleased to announce
that Andrew Unitt is being appointed to the Board as a
non-executive director with effect from 1 January 2022. Andrew will
replace Jonathan Freeman who will be stepping down as senior
independent non-executive director on the 31 of December 2021.
Andrew spent eleven years at Boots plc, where he was Finance
Director for four years of Boots Healthcare International, its
over-the-counter medicines business. Andrew is currently a
non-executive director of AIM company, Oncimmune Holdings Plc and
was previously Chief Financial Officer at the University of
Nottingham until July 2016. Prior to working in higher education,
Andrew was a Finance Director for 20 years in a wide range of
industries. Andrew has also held several non-executive
directorships within the NHS and private sector.
Commenting on the appointment, James Barder, Chief Executive
Officer of the Company, said: " Andrew is a welcome addition to the
Futura Medical Board at this particular stage of the Company. His
strong financial experience, OTC market expertise and exceptional
skills in strategic development and business management will
further enhance our ambition and focus as we execute
commercialisation of MED3000 as a global brand, strengthen our
distribution network and continue to accelerate Company growth
towards long term, sustainable revenues. On behalf of the Board, I
would like to thank Jonathan for his long standing commitment and
support to Futura over the years. His contribution is very much
appreciated, and I wish him all the best in his future
commitments."
MED3000 is a topically applied gel which utilises our
proprietary DermaSys(R) technology, developed specifically for
treatment of ED. MED3000 has the potential to be a highly
differentiated product by addressing significant unmet needs in the
ED market as well as being available without a doctor's
prescription where approved by regulators.
In accordance with Schedule 2(g) of the AIM Rules, Andrew
Vaughan Unitt (aged 64) holds or has held directorships in the
following companies:
Current Directorships Past Directorships held in the past
EMTEC Colleges Limited five years
Nottingham College Services Limited None
Oncimmune Holdings Plc
In accordance with Schedule 2(g)(v), Andrew Unitt was a director
at the time of or within the twelve months preceding the following
events, with all companies being part of the same group:
Directorship Directorship held until Event
Focus (DIY) Limited 21 June 2010 Entered into a corporate voluntary arrangement on 24
August 2009, then into administration
on 5 May 2011 and then into a creditors voluntary
liquidation on 26 October 2012
Focus DIY (Investments)Limited 21 June 2010 Entered into administration on 5 May 2011
Focus No.1 Limited 21 June 2010 Entered into a creditors' voluntary arrangement on 24
August 2009 and into a creditors voluntary
liquidation on 9 August 2009
Do It All (Holdings) Limited 21 June 2010 Entered into administration on 5 May 2011
Do It All Limited 21 June 2010 Entered into a corporate voluntary arrangement on 24
August 2009 and then into administration
on 5 May 2011
Payless DIY Limited 21 June 2010 Entered into a corporate voluntary arrangement on 24
August 2009 and then into administration
on 5 May 2011
Payless Properties Limited 21 June 2010 Entered into administration on 5 May 2011
For further information please contact:
Futura Medical plc
James Barder, Chief Executive
Angela Hildreth, Finance Director and COO
Email: Investor.relations@futuramedical.com
Tel: +44 (0) 1483 685 670
Nominated Adviser and Sole Broker:
Liberum
Richard Lindley/ Euan Brown/ Kane Collings
Tel: +44 (0) 203 100 2000
For media enquiries please contact:
Optimum Strategic Communications
Mary Clark/ Eva Haas/ Hollie Vile
Email: futuramedical@optimumcomms.com
Tel: +44 (0) 203 922 0891
Notes to editors:
About Futura Medical plc
Futura Medical plc (AIM: FUM), is a pharmaceutical company
developing a portfolio of innovative products based on its
proprietary, transdermal DermaSys(R) technology. Each DermaSys(R)
formulation is separately patented and specifically tailored for
the selected indication and application, as well as being optimised
for clinical efficacy, safety, administration and patient
convenience. The products are developed for the prescription and
consumer healthcare markets as appropriate. Current therapeutic
areas are sexual health, including erectile dysfunction, and pain
relief. Development and commercialisation strategies are designed
to maximise product differentiation and value creation whilst
minimising risk.
MED3000 is Futura's topical gel formulation that is a
breakthrough treatment for erectile dysfunction (ED) through a
unique evaporative mode of action. Futura has conducted a Phase 3
study using MED3000 in ED, referred to as "FM57". This was a 1,000
patient, dose-ranging, multi-centre, randomised, double blind,
placebo-controlled, home use, parallel group study delivering
highly statistically significant results compared to pre-treatment
baseline, consistently meeting all co-primary endpoints of IIEF,
SEP2 and SEP3 (internationally accepted clinical trial endpoints in
ED) with over 60% of patients experiencing a clinically meaningful
improvement in their ED. MED3000 also begins to work immediately in
some patients, with 60% of patients seeing onset of their erection
within 10 minutes of application. MED3000 is CE marked in Europe
and the UK as a clinically proven topical treatment for adult men
with erectile dysfunction.
Futura is based in Guildford, Surrey, and its shares trade on
the AIM market of the London Stock Exchange.
www.futuramedical.com
This information is provided by RNS, the news service of the
London Stock Exchange. RNS is approved by the Financial Conduct
Authority to act as a Primary Information Provider in the United
Kingdom. Terms and conditions relating to the use and distribution
of this information may apply. For further information, please
contact rns@lseg.com or visit www.rns.com.
RNS may use your IP address to confirm compliance with the terms
and conditions, to analyse how you engage with the information
contained in this communication, and to share such analysis on an
anonymised basis with others as part of our commercial services.
For further information about how RNS and the London Stock Exchange
use the personal data you provide us, please see our Privacy
Policy.
END
MSCFLFLAIILDFIL
(END) Dow Jones Newswires
October 28, 2021 02:00 ET (06:00 GMT)
Grafico Azioni Futura Medical (LSE:FUM)
Storico
Da Feb 2024 a Mar 2024
Grafico Azioni Futura Medical (LSE:FUM)
Storico
Da Mar 2023 a Mar 2024